TEACH survey, a prospective survey on the incidence of venous thromboembolic events during chemotherapy for solid tumors

• Conditions: cancer; malign tumors; 10027655; 10014523

• Registration Number: NL-OMON30286
• Lead Sponsor: European Organisation for Research and Treatment of Cancer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

- Age >= 18 years
- Patients who are scheduled to receive chemotherapy of >= 3 months
duration for cytologically or histologically proven:
o breast cancer (metastatic)
o colorectal cancer ((neo-) adjuvant or palliative chemotherapy)
o gastric cancer ((neo-) adjuvant or palliative chemotherapy)
o lung cancer ((neo-) adjuvant or palliative chemotherapy)
o ovarian cancer ((neo-) adjuvant or palliative chemotherapy)
o pancreatic cancer ((neo-) adjuvant or palliative chemotherapy)
o prostate cancer (hormone-refractory)
- Life expectancy of more than 3 months
- Informed consent given by patient for data collection and
ultrasonography

Exclusion Criteria

- No chemotherapy within 6 weeks before the start of the observation
period
- No major surgery including surgery for cancer within 4 weeks before the
start of the observation period
Note: minor surgery, e.g. implant of a port-a-cath, within these 4 weeks is
allowed.
- No major surgery including surgery for cancer planned during the
observation period
Note: Radiotherapy before or during the observation period is allowed.
- Patients with a history of DVT or PE can be included if treatment and
secondary prevention of the last episode was completed prior to survey
entry.
- No concurrent or scheduled use of thrombo-prophylaxis or any
anticoagulant therapy such as parenteral anticoagulants (heparin, low
molecular weight heparins or other agents such as fondaparinux,
bivalirudin), oral anticoagulants (vitamin K antagonists) or thrombolytic
agents

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is a composite of any of the following outcomes:<br /><br>* asymptomatic proximal deep vein thrombosis of the lower limbs<br /><br>* confirmed symptomatic deep vein thrombosis of the lower limbs<br /><br>* confirmed pulmonary embolism</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>